Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Intensiteit behandeling endeldarmkanker afgenomen
feb 2024 | Chirurgie, Endoscopie, Maag-darm-leveroncologie, Radiotherapie